Nanocurcumin Improves the Therapeutic Role of Mesenchymal Stem Cells in Liver Fibrosis Rats

Nano-curcumin (Nano-Cur) is a promising therapeutic agent that has a wide array of effective medicinal potentials. Therefore, the present inquiry aimed to assess Nano-Cur's impact on the therapeutic effect of bone-marrow-derived mesenchymal stem cells (BM-MSCs) in the rat model of liver fibrosis prompted by carbon tetrachloride (CCl4). Liver fibrosis was developed in 30male Wistar albino rats which were divided into five groups, six animals each. The 1st group (CCl4 group) was sacrificed immediately after the induction of liver fibrosis. The 2nd group received a single iv injection of BM-MSCs and left for 4weeks, the3rd group received 100mg/kg b.w. Nano-Cur 3times/week for 4weeks, the 4th group received a single iv injection of 107 BM-MSCs accompanied with Nano-Cur 3times/week for 4weeks, and the 5th group left for 4weeks without any intervention. Data revealed that treatment with BM-MSCs plus Nano-Cur alleviated liver fibrosis through reducing liver oxidative stress and restoring both liver histological picture and enzymatic profile. Additionally, companied treatment resulted in reducing TGFβ1 levels and attenuating the expression of Smad 2,3 and collagen I, III genes. Conversely, most of the pathological lesions were still detected in the recovery group. Nano-Cur improves the therapeutic role of BM-MSCs in liver fibrosis rats.